<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                              May 8, 2025

Brian Hahn
Principal Executive and Financial Officer
GlycoMimetics, Inc.
P.O. Box 65
Monrovia, MD 21770

       Re: GlycoMimetics, Inc.
           Amendment No. 2 to Registration Statement on Form S-4
           Filed April 28, 2025
           File No. 333-285035
Dear Brian Hahn:

     We have reviewed your amended registration statement and have the
following
comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments. Unless
we note
otherwise, any references to prior comments are to comments in our April 22,
2025 letter.

Amendment No. 2 to Registration Statement on Form S-4
Proposal No. 4 - The Redomestication Proposal
U.S. Federal Income Tax Considerations of the Cayman Redomestication, page 239

1.     We note your response to prior comment 2, including the form of legal
opinion filed
       as Exhibit 8.1 to the registration statement. If you intend for the
exhibit to constitute a
       short-form opinion, please revise your registration statement to clearly
state that the
       disclosure in this section is the opinion of counsel and clearly
articulate the opinion
       being rendered. Refer to Section III.B.2 of Staff Legal Bulletin No. 19
(CF), available
       on our website. In addition, please file an executed copy of the opinion
prior to
       effectiveness. Refer to Sections III.D.2 and III.D.3 of the Staff Legal
Bulletin.
 May 8, 2025
Page 2
Crescent's Business
Our solution, CR-001
In vitro activity, page 283

2.     We note from your response to prior comment 15 that the data presented
in the graph
       on the right side of the graphic in this section was not statistically
significant. Please
       revise to make that clear.

       Please contact Jenn Do at 202-551-3743 or Kevin Vaughn at 202-551-3494
if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jessica Dickerson at 202-551-8013 or Tim Buchmiller at 202-551-3635
with any
other questions.



                                                              Sincerely,

                                                              Division of
Corporation Finance
                                                              Office of Life
Sciences
cc:   Kostian Ciko, Esq.
</TEXT>
</DOCUMENT>
